The mean TMB was 4.0 ± 1.9 for RET+ NSCLC (N = 65), 2.6 ± 1.6 for RET+ thyroid cancer (N = 52), both of which were significantly lower than RET+ CRC. This evidence concerns the gene RET and non-small cell lung carcinoma.